Special Report Download
Statins: A Comparative Safety AnalysisStatins are among the most widely taken prescription medications in the world mainly because they have been shown to reduce the risk of cardiovascular disease. Their safety profiles, however, are still topics of great debate.
The following report is a detailed examination of post-marketing side effect data aimed at answering two questions:
1) Which of the many suspected side effect types are supported by FAERS reporting trends?
2) How do the post-marketing safety profiles differ between the statins?
Drugs included in the analysis are:
- Caduet (amlodipine and atorvastatin)
- Crestor (rosuvastatin), Lescol (fluvastatin)
- Lipitor (atorvastatin)
- Livalo (pitavastatin)
- Mevacor (lovastatin)
- Pravachol (pravastatin)
- Simcor (niacin and simvastatin)
- Vytorin (ezetimibe and simvastatin),
- Zocor (simvastatin).
This analysis of post-marketing AE data regarding statins showed disproportionally elevated reporting for a number of AEs that can adversely affect treatment adherence and quality of life. AE reporting rates differed strikingly for drugs within the class